AMIX Company Profile and Key Details

AMIX has shown weak momentum, losing -7.9% over the past week and -58.83% over the past quarter, though year-to-date performance is down -15.42%. Short-term trend indicators are bullishly aligned (SMA20 5.92%, SMA50 -13.63%, SMA200 -60.73%). The stock’s 14-day RSI is 47.41 (neutral), while the ATR of 0.04 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -86.34% below its high and over 20.03% above its low. Average 10-day trading volume of 4.34 million shares is significantly above the 3-month average of 664.70 thousand, indicating heightened recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers 1685.71% upside. The low target suggests 1685.71% downside. The mean target is $5.00. This offers 1685.71% upside. Autonomix Medical, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended February 11, 2026, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -39.17% in February 13, 2025.

Autonomix Medical, Inc. Common Stock has 11.41 million shares outstanding. The public float is 11.06 million shares, elevated short interest at 2.05% of float. This equals 230.95 thousand shares. The short ratio is 1.81 days. Institutional investors hold 5.13% of the float. Insiders own 6.93%.

Autonomix Medical, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.07. This means the shares are trading below this model’s fair value.

Autonomix Medical, Inc. Common Stock (NASDAQ:AMIX) closed at $0.28 USD, losing -$0.03 (-10.00%) from the previous close of $0.32. The stock is currently mid-range between its 52-week high and low $0.20 and $2.64. With a market capitalization of about $1.46 million, Autonomix Medical, Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.80). Key stats such as the average daily volume over the past year has been around 627.87 thousand shares, trading with heavier-than-usual volume. Headquartered in The Woodlands, None, Autonomix Medical, Inc. Common Stock operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Bradley Hauser, the company employs approximately 5 people and listed since January 29, 2024. Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system.

Autonomix Medical, Inc. Common Stock trades at a P/E ratio of -0.14, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.27 suggesting the stock is closer to book value. The P/FCF stands at -0.12, also above market averages.

Our AI price prediction model suggests that Autonomix Medical, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.27%, with price expected at $0.28 by June 02, 2026, within a range of $0.26 to $0.30 3-Month Outlook: Projected fall of -68.27%, reaching $0.09 by August 14, 2026, with a range of $0.00 to $0.25. 1-Year Outlook: Projected loss of -89.42%, with price at $0.03 by May 19, 2027, within a range of $0.00 to $0.56.

Autonomix Medical, Inc. Common Stock (NASDAQ:AMIX) shares are down -15.42% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Autonomix Medical, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.14. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.00, suggesting 1663.05% upside. Our AI forecast model points to short-term weakness (-1.27% over two weeks), a medium-term fall (-68.27% over three months), and a longer-term loss (-89.42% over one year), with expected trading ranges indicating moderate volatility.